Literature DB >> 16083208

Pneumocystis pneumonia: an update.

Sureeporn Sritangratanakul1, Surang Nuchprayoon, Issarang Nuchprayoon.   

Abstract

Pneumocystis pneumonia is a major cause of illness and death in immunocompromised hosts. The numbers of pneumocystis pneumonia cases in Thailand have increased each year from 1992 to 2000 and peaked in 2000 at 6,255 cases. The microbe that causes pneumocystis pneumonia in humans is called Pneumocystis jirovecii. Pneumocystis sp. was discovered nearly a century ago, but the knowledge of Pneumocystis sp. remained poorly understood, until the molecular biology techniques help scientists verify it fungus nature. In the past, Pneumocystis sp. was misclassified as protozoan due to its morphologic features. Later, it was reclassified as fungus due to DNA analysis. Cotrimaxazole, the combination of trimethoprim-sulfamethoxazole, is the drug of choice for treatment and prophylaxis of pneumocystis pneumonia. However, increasing evidence of mutations in the enzyme dihydropteroate synthase (DHPS), the target of sulfa drugs represent emergence of sulfa resistance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16083208

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  2 in total

1.  FlindersTechnology Associates (FTA) filter paper-based DNA extraction with polymerase chain reaction (PCR) for detection of Pneumocystis jirovecii from respiratory specimens of immunocompromised patients.

Authors:  Surang Nuchprayoon; Wilai Saksirisampant; Siraya Jaijakul; Issarang Nuchprayoon
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

Review 2.  Pneumocystis jirovecii pneumonia in developing countries.

Authors:  Y de Armas Rodríguez; G Wissmann; A L Müller; M A Pederiva; M C Brum; R L Brackmann; V Capó de Paz; E J Calderón
Journal:  Parasite       Date:  2011-08       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.